Celcuity Inc. (CELC) Stock Analysis
Healthcare · Biotechnology · NasdaqCM
Celcuity Inc. (CELC) posted $0 in revenue for fiscal 2025, with a net loss of $177.04M, per its SEC filings.
Data last refreshed August 2, 2026 from SEC filings · how we compute this
The analyst's take on Celcuity Inc.
Celcuity Inc. has grown revenue from $0 to $0 over the last 10 fiscal years.
It carries about $321.85M of total debt.
The one thing worth a second look in the filings is share count rising (dilution).
Synthesised from Celcuity Inc.'s SEC filings — descriptive, not advice. Ask the analyst your own question →
Celcuity Inc. revenue & earnings — last 10 fiscal years
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross profit | — | — | — | — | — | — | — | — | — | — |
| Net income | $-3.31M | $-6.25M | $-7.48M | $-7.36M | $-9.47M | $-29.61M | $-40.37M | $-63.78M | $-111.78M | $-177.04M |
| Net margin | — | — | — | — | — | — | — | — | — | — |
Source: Celcuity Inc. SEC filings (10-K).
Celcuity Inc.: 2 potential red flags in the filings
Patterns in the filed statements worth a second look — computed and cited, not AI guesswork, and not a signal to sell. The kind of thing that hides in a 10-K.
- Share count rising (dilution)Shares outstanding grew 223.4% over 4 years (14.9M → 48.2M) — existing holders' stakes are being diluted.
- Debt with negative operating cash flowCarries $321.9M of debt while last year's operating cash flow was negative ($-153.3M).
Explore 10 years of Celcuity Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track CELC in your portfolio →
Celcuity Inc. financial history by metric
About Celcuity Inc.
Celcuity Inc., a clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's lead drug candidate includes Gedatolisib, which selectively targets various Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2 to treat patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) or HR+/HER2-, advanced or metastatic breast cancer (ABC), and patients with metastatic castration resistant prostate cancer (mCRPC). The company had a license agreement with Pfizer Inc. for the development and commercialization rights to Gedatolisib. Celcuity Inc. was incorporated in 2011 and is based in Minneapolis, Minnesota.
Celcuity Inc. — frequently asked questions
What is Celcuity Inc.'s revenue?
Celcuity Inc. (CELC) reported revenue of $0 for fiscal year 2025, according to its SEC filings.
Is Celcuity Inc. profitable?
No — CELC reported a net loss of $-177.04M in fiscal 2025.
What is CELC's P/E ratio?
Celcuity Inc. trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How much debt does Celcuity Inc. have?
As of fiscal year 2025, CELC carried roughly $321.85M in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Celcuity Inc.'s market cap?
Celcuity Inc. (CELC) has a market capitalization of about $4.42B, based on the latest data in our nightly-refreshed cache.
When does Celcuity Inc.'s fiscal year end?
CELC's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
Where does this data come from?
All figures are computed from Celcuity Inc.'s official SEC filings (10-K and 10-Q), covering 10 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.